The EFSA issued scientific opinions concluding and recommending on the effectiveness of the disease control measures laid down in Delegated Regulation (EU) 2020/687 for each category A disease5, in particular on the effectiveness of the monitoring period, of the radiuses of the protection and surveillance zones, and on the duration of the measures to be applied in those zones, as laid down in Annexes II, V, X and XI to Delegated Regulation (EU) 2020/687. In addition, prohibitions in restricted zones and risk-mitigating treatments for products of animal origin and other materials, as laid down in Annexes VI, VII and VIII to Delegated Regulation (EU) 2020/687 have been assessed by EFSA, and conclusions on the effectiveness of those measures and risk-mitigation treatments have been published in a scientific opinion on the ‘Assessment of the control measures of the Category A diseases of the Animal Health Law: prohibitions in restricted zones and risk-mitigating treatments for products of animal origin and other materials’ [Assessment of the control measures of the Category A diseases of the Animal Health Law: prohibitions in restricted zones and risk-mitigating treatments for products of animal origin and other materials, https://efsa.onlinelibrary.wiley.com/doi/epdf/10.2903/j.efsa.2022.7443.]. Therefore, Annexes II, V to VIII, X and XI to Delegated Regulation (EU) 2020/687 should be amended, to take account of the effective measures, prohibitions and risk-mitigating treatments relevant for each category A disease in accordance with EFSA recommendations. In addition, following the amendment of Article 27(3) of Delegated Regulation (EU) 2020/687, Annex VII to that Delegated Regulation should be amended to also include the methods for mitigating the risk of the derived products from the restricted zone.
Recital 28, Regulation (EU) 2026/322
In forcesince 12 Feb 2026